• Normal young adult macaques – To test cognitive effects of any compound (PAL, DMTS, OR)
  • Ketamine-treated young adult macaques – Model of cognitive deficits in schizophrenia (PAL, DMTS, OR)
  • Scopolamine-treated young adult macaques – Model of cognitive deficits in Alzheimer’s disease (PAL, DMTS, OR)
  • Normal aged macaques (20 – 25 years old) – Model of cognitive deficits in mild cognitive impairment (MCI) and Alzheimer’s disease (PAL, DMTS, ID/ED, OR)
  • Chronic low-dose MPTP-treated macaques – Model of cognitive deficits in Parkinson’s disease, ADHD and schizophrenia (VDR, CPT, ID/ED, OR)